oxybutynin has been researched along with HIV Infections in 5 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Qutenza (capsaicin) 8% patch is used to treat various neuropathic indications, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN)." | 8.90 | Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. ( Katz, NP; Mou, J; Paillard, F; Stoker, M; Trudeau, J; Turnbull, B, 2014) |
| "Qutenza (capsaicin) 8% patch is used to treat various neuropathic indications, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN)." | 4.90 | Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. ( Katz, NP; Mou, J; Paillard, F; Stoker, M; Trudeau, J; Turnbull, B, 2014) |
| " Transdermal drug delivery offers several distinct advantages over traditional dosage forms." | 2.52 | Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors. ( Buckheit, RW; Ham, AS, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blair, HA | 1 |
| Simpson, DM | 1 |
| Brown, S | 1 |
| Tobias, JK | 1 |
| Vanhove, GF | 1 |
| Mou, J | 1 |
| Paillard, F | 1 |
| Turnbull, B | 1 |
| Trudeau, J | 1 |
| Stoker, M | 1 |
| Katz, NP | 1 |
| Ham, AS | 1 |
| Buckheit, RW | 1 |
| Vogler, MA | 1 |
| Patterson, K | 1 |
| Kamemoto, L | 1 |
| Park, JG | 1 |
| Watts, H | 1 |
| Aweeka, F | 1 |
| Klingman, KL | 1 |
| Cohn, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy[NCT00064623] | Phase 3 | 300 participants | Interventional | 2003-08-31 | Completed | ||
| A Phase II Pharmacokinetic Study of the Transdermal Contraceptive System and Oral Contraceptive in HIV-1 Infected Women on Lopinavir/Ritonavir[NCT00125983] | Phase 2 | 32 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for oxybutynin and HIV Infections
| Article | Year |
|---|---|
Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain.
Topics: Administration, Cutaneous; Analgesics; Capsaicin; HIV Infections; Humans; Neuralgia; Neuralgia, Post | 2018 |
Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients.
Topics: Adult; Aged; Aged, 80 and over; Capsaicin; Databases, Factual; Dose-Response Relationship, Drug; Dou | 2014 |
Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors.
Topics: Administration, Cutaneous; Animals; Anti-HIV Agents; Chemistry, Pharmaceutical; Drug Delivery System | 2015 |
2 trials available for oxybutynin and HIV Infections
| Article | Year |
|---|---|
NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study.
Topics: Adult; Capsaicin; Double-Blind Method; Endpoint Determination; Female; HIV Infections; Humans; Kapla | 2014 |
Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.
Topics: Adolescent; Adult; Contraceptives, Oral, Combined; Drug Combinations; Drug Interactions; Estrogens; | 2010 |